MIF

Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022

Retrieved on: 
Wednesday, October 26, 2022
Risk, MIF, Infection, MFE, Habo, COVID-19, Guangdong-Hong Kong-Macau Greater Bay Area, R, TCM, Methyltrichlorosilane, Casino, Vaccine, Yiling District

SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened on October 20, 2022.

Key Points: 
  • SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened on October 20, 2022.
  • As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo.
  • As an international and frontier city of the Guangdong-Hong Kong-Macau Greater Bay Area, Macau becomes a good place for TCM international communication.
  • Yiling's Lianhua health products were also selected as official anti-epidemic products and handed out to visitors.

Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022

Retrieved on: 
Wednesday, October 26, 2022
Risk, MIF, Infection, MFE, Habo, COVID-19, Multimedia, Guangdong-Hong Kong-Macau Greater Bay Area, R, TCM, Methyltrichlorosilane, Casino, Vaccine, Yiling District

SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened on October 20, 2022.

Key Points: 
  • SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened on October 20, 2022.
  • As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo.
  • As an international and frontier city of the Guangdong-Hong Kong-Macau Greater Bay Area, Macau becomes a good place for TCM international communication.
  • Yiling's Lianhua health products were also selected as official anti-epidemic products and handed out to visitors.

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

Retrieved on: 
Thursday, September 29, 2022
Software, General Health, Pharmaceutical, Oncology, Data Management, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Institute, Precision medicine, Corporation, Histology, Doctor of Philosophy, Armed Forces Institute of Pathology, TMA, Quality control, MIF, Industry, Noise, Solution, Documentation, Tumor microenvironment, Research, University of Bern, University, TRU, Medical imaging, Pathology

Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.

Key Points: 
  • Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.
  • ngTMA supports research collaborators with an interdisciplinary approach to studying tumor biology and disease states.
  • We are thrilled to be partnering with ngTMA to jointly empower biopharma customers with tissue multiplex services.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Hyundai CRADLE to Host 7th Mobility Innovators Forum Under the Theme 'Orchestrating Ecosystems'

Retrieved on: 
Tuesday, September 20, 2022
University, Palace, California Energy Commission, Fontinalis, Economics, Investment, Hyundai Motor Group, French Alternative Energies and Atomic Energy Commission, Ecosystem, Silicon, Multimedia, MIF, Hyundai, SVP, Mobile phone, Video game, Entertainment, Group

Hyundai CRADLE Silicon Valley will host the seventh Mobility Innovators Forum on September 22nd at the Palace of Fine Arts, San Francisco

Key Points: 
  • Hyundai CRADLE Silicon Valley will host the seventh Mobility Innovators Forum on September 22nd at the Palace of Fine Arts, San Francisco
    SEOUL, South Korea and MOUNTAIN VIEW, Calif., Sept. 20, 2022 /PRNewswire/ -- Hyundai Motor Group (the Group) announced today that Hyundai CRADLE Silicon Valley will host the seventh annual Mobility Innovators Forum (MIF) on September 22nd at the Palace of Fine Arts, San Francisco.
  • Under the theme of 'Orchestrating Ecosystems,' participants will showcase and discuss how best to harmonize the interconnected innovations of mobility ecosystems to make a human-centered mobility future a reality.
  • "We are extremely excited to return to an in-person event at the Palace of Fine Arts in San Francisco with a distinguished roster of speakers for the MIF addressing this year's theme of 'Orchestrating Ecosystems' for human-centered mobility," said Henry Chung, SVP and Head of Hyundai CRADLE Silicon Valley.
  • On the MIF website , visitors can learn more about the Group's diverse innovations through digital content at MIF Channel.

DGAP-News: Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, GLOBE, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

OncoOne Expands Scientific Advisory Board Adding Three World-Renowned MIF and Macrophage Experts to Support Upcoming Clinical Programs

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard Medical School, Neoplasm, University, Breast cancer, HIV disease progression rates, CEO, Division, Research, Degenerative disease, Physician, University of Louisville School of Medicine, Immune tolerance, Microbiology, Macrophage, SAB, Dana–Farber Cancer Institute, International Association for Physicians in Aesthetic Medicine, QJM, Trinity, Phenotype, Department, Homeostasis, Biochemistry, Cytokine, Trinity College, Molecular medicine, Goal, Immunology, Hospital, Leadership, MIF, Company, Publication, Tumor-associated macrophage, Lead, Association, Quarterly Journal, Molecular genetics, Society for Immunotherapy of Cancer, Society, Trinity College Dublin, Patient, Pharmaceutical industry, Vaccine, Medicine, Immunotherapy, Cancer, Brigham

oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.

Key Points: 
  • oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.
  • The new members of the OncoOne Scientific Advisory Board include:
    Dr. Seamas Donnelly is Professor of Medicine at Trinity College Dublin.
  • He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies.
  • OncoOne seeks to overcome the limitations of targeting the macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform of MIF, the oxidized macrophage migration inhibitory factor (oxMIF).

Artificial Intelligence-powered (AI) Spatial Biology Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, August 30, 2022
Partnership, Analysis, RNA, Research, Translational research, Artificial intelligence, Government, Prophet, Comprehension, Solution, Artificiality, Precision medicine, Tissue, Machine learning, Recurrence, Pathology, MIF, Drug discovery, Molecular biology, DNA, Intelligence, Prognosis, Gene expression, Cell, Cell biology, Software as a service, Biology, CAGR, Immunotherapy, Forecast, Invention, AI, Development, CRO, Medical device, Microscope, Medical imaging, Fine chemical

In recent years, enormous advances in biological research and automated molecular biology have been gained using artificial intelligence (AI).

Key Points: 
  • In recent years, enormous advances in biological research and automated molecular biology have been gained using artificial intelligence (AI).
  • It is predicted that using AI on cell-by-cell maps of gene or protein activity will lead to major inventions in spatial biology.
  • Artificial Intelligence in spatial biology has gained faster development in sequencing and analysis, drug discovery, and disease diagnosis.
  • Global Artificial Intelligence-powered (AI) Spatial Biology Market, by Data Analyzed, 2022-2030 (Value US$ Mn)

Artificial Intelligence-powered (AI) Spatial Biology Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, August 30, 2022
Partnership, Analysis, RNA, Research, Translational research, Artificial intelligence, Government, Prophet, Comprehension, Solution, Artificiality, Precision medicine, Tissue, Machine learning, Recurrence, Pathology, MIF, Drug discovery, Molecular biology, DNA, Intelligence, Prognosis, Gene expression, Cell, Cell biology, Software as a service, Biology, CAGR, Immunotherapy, Forecast, Invention, AI, Development, CRO, Medical device, Microscope, Medical imaging, Fine chemical

In recent years, enormous advances in biological research and automated molecular biology have been gained using artificial intelligence (AI).

Key Points: 
  • In recent years, enormous advances in biological research and automated molecular biology have been gained using artificial intelligence (AI).
  • It is predicted that using AI on cell-by-cell maps of gene or protein activity will lead to major inventions in spatial biology.
  • Artificial Intelligence in spatial biology has gained faster development in sequencing and analysis, drug discovery, and disease diagnosis.
  • Global Artificial Intelligence-powered (AI) Spatial Biology Market, by Data Analyzed, 2022-2030 (Value US$ Mn)

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)